Clinical Trial

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Name: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — clinical trial record (NCT06008119)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, open-label, Phase 3 study

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-08-15; most recent amendment 2025-09-12.

Status change: Not Yet Recruiting → Recruiting 2025-02-26

Trial Details

NCT Number	NCT06008119
Lead Sponsor	Shanghai Kechow Pharma, Inc.
Conditions	Colorectal Cancer Metastatic
Enrollment	165 participants
Start Date	2023-10-25
Primary Completion	2026-12-24 (estimated)
Study Completion	2026-12-24 (estimated)
Updated on ClinicalTrials.gov	2025-09-18